(NASDAQ: HRTX) Heron Therapeutics's forecast annual revenue growth rate of 11.49% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Heron Therapeutics's revenue in 2025 is $144,285,000.On average, 2 Wall Street analysts forecast HRTX's revenue for 2025 to be $23,938,594,754, with the lowest HRTX revenue forecast at $23,611,086,140, and the highest HRTX revenue forecast at $24,266,103,368. On average, 1 Wall Street analysts forecast HRTX's revenue for 2026 to be $27,114,666,664, with the lowest HRTX revenue forecast at $27,114,666,664, and the highest HRTX revenue forecast at $27,114,666,664.
In 2027, HRTX is forecast to generate $30,496,383,518 in revenue, with the lowest revenue forecast at $30,496,383,518 and the highest revenue forecast at $30,496,383,518.